PARP1 and glioblastoma: The advantage of AE-based PARP-ligand therapy would be, first of all, the ability to use radionuclide therapy in tumors with genomic instability, such as TNBC, GBM, and pancreatic adenocarcinoma, for which there are currently no clinically available radionuclide-based options with beta or alpha emitters.